Endometrial Cancer Trial, Recruiting NCT04453904 Sponsor: Peking University People's Hospital Condition: Endometrial Cancer
Back to Endometrial Cancer

Endometrial Cancer Trial, Recruiting

NCT04453904
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are receiving primary (first-time) treatment for their condition
  • People who have had a full staging surgery, including removal of the uterus, both ovaries, and fallopian tubes, along with surgical staging
  • People whose post-surgery tissue samples confirmed a diagnosis of endometrial adenocarcinoma (a specific type of uterine cancer)
  • People whose cancer has been classified as Stage III endometrial cancer according to the FIGO 2009 staging system
  • People who are enrolling within 8 weeks of their surgery date
  • People whose blood and organ function results meet the required levels, including healthy white blood cell counts, platelet counts, liver function markers, and kidney function markers (confirm specific values with the trial site)
  • People with a Karnofsky performance score of 60 or above, which is a measure of general health and ability to carry out daily activities
  • People who are willing to participate voluntarily, sign a consent form, and attend follow-up appointments

Who may not be able to join:

  • People who have already received any additional treatment after surgery, such as radiation therapy, chemotherapy, or hormone therapy
  • People who had visible tumour remaining in the body after their surgery
  • People who have another active cancer of a serious nature
  • People with certain heart conditions, including a heart attack within the past 3 months, unstable chest pain, or uncontrolled irregular heartbeat, that would prevent them from safely receiving radiation or chemotherapy
  • People whose estimated life expectancy is less than 6 months
  • People who are unable or unwilling to follow the requirements of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +861088324381

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University People's Hospital
Registry
ClinicalTrials.gov
Start date
12 May 2020
Est. completion
1 April 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progress-free survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov